Disease-burden-adapted immunotherapy protocol for primary refractory or high-risk relapsed pediatric acute lymphoblastic leukemia

Hemasphere. 2024 Jul 29;8(8):e111. doi: 10.1002/hem3.111. eCollection 2024 Aug.
No abstract available